Chandan Healthcare Limited is a leading integrated diagnostic and pharmacy service provider in North India, operating a high-integrity **Company-Owned and Company-Operated (COCO)** model. Established in 2003 and listed on the **NSE Emerge** in February 2025, the company has evolved from a regional player in Uttar Pradesh and Uttarakhand into a pan-India healthcare contender. By integrating pathology, advanced radiology, and retail pharmacy, Chandan offers a "one-roof" solution that distinguishes it from franchise-heavy competitors. --- ### **Integrated Business Model & Revenue Verticals** Chandan operates a synergistic model where retail pharmacies serve as diagnostic collection points, and diagnostic centers drive pharmacy footfall. The company is strategically shifting its revenue mix toward a target of **80% Diagnostics and 20% Pharmacy** over the next three years to capture higher-margin pathology and radiology growth. | Segment | FY25 Revenue | Revenue Share | Key Offerings & Infrastructure | | :--- | :--- | :--- | :--- | | **Pathology** | **₹96.50 Cr** | **41.94%** | **1,496 total tests** (481 routine, 1,015 specialized). Includes Genomics and Molecular Diagnostics. | | **Radiology** | **₹27.80 Cr** | **12.08%** | **3 Tesla MRI**, **128-slice CT**, 4D Ultrasound, PET scans, and Digital X-Ray. | | **Pharmacy** | **₹105.80 Cr** | **45.98%** | **27 retail outlets** providing genuine medicines at concessional prices. | --- ### **Operational Infrastructure: The Hub-and-Spoke Framework** The company utilizes a tiered infrastructure model to penetrate Tier 2 and Tier 3 cities while maintaining centralized expertise for complex testing. The network is supported by **16 NABL-accredited labs**, **10 NABH-accredited centres**, and a workforce of over **1,800 skilled professionals**. * **Large Centres (22):** Flagship facilities (**8,000–9,000 sq. ft.**) offering comprehensive MRI and advanced imaging. * **Medium Centres (29):** Equipped with CT facilities and essential imaging. * **Small Centres (11):** Basic diagnostics catering to underserved regions. * **Collection Centres (400+):** Extensive network for last-mile connectivity. * **Chandan Medical Centres (CMCs):** Community hubs integrating sample collection, pharmacy, and teleconsultation. The company plans to launch **20+ new CMCs annually**. --- ### **Strategic Growth Pillars & Market Expansion** Chandan is transitioning from a regional leader to a national provider through a multi-pronged expansion strategy: * **National Footprint:** While **Uttar Pradesh (70%)** and **Uttarakhand (30%)** are core markets, the company has recently entered **Haryana, Bihar, Maharashtra, West Bengal, Chhattisgarh, and Madhya Pradesh**. * **Network Targets:** Planning to develop **100 labs** and over **1,000 franchise collection points** across **17 states** within the next **3 years**. * **Institutional Exclusivity:** A landmark **5-year strategic partnership** with **Jeena Sikho Lifecare** makes Chandan the exclusive diagnostic partner for **100+ clinics** across **23 states**, ensuring "day-one profitability" for new labs. * **Public-Private Partnerships (PPP):** Secured high-value government contracts, including a **10-year, ₹550 Cr** estimated project in **Punjab** for MRI/CT services and a **10-year** project at **NFRCH, Malegaon, Assam**. * **Inorganic Growth:** Recent acquisitions of **Nishkam Imaging (Delhi)** and **X Life Diagnostics (Patna)** have accelerated entry into high-demand metro markets. --- ### **Technology, Innovation & Specialized Diagnostics** Chandan is moving up the value chain by focusing on high-growth segments like **Cancer, IVF, and Genetics**. * **Genome Lab (Lucknow):** Expected to be operational by **mid-2026**, this facility will focus on **Whole-Genome Sequencing (WGS)**, **Transcriptomics**, and **Pharmacogenomics**. * **Precision Equipment:** Utilization of **Closed PCR Systems** (Roche/Abbott) and high-end imaging like the **3T Magnetom Lumina MRI** and **384-slice CT** scanners. * **Digital Ecosystem:** The **Chandan 24x7 App** (**100K+ downloads**) integrates lab bookings, teleconsultations, and e-pharmacy services. * **CAPEX Efficiency:** Strategic use of refurbished high-end machinery allows the company to optimize capital expenditure while maintaining diagnostic accuracy. --- ### **Financial Performance & Scaling Metrics** The company has demonstrated explosive growth, with a **559.82% surge in PAT** between **FY23 and FY25**. | Particulars (₹ Cr) | 9M FY26 | FY25 (Full Year) | FY24 (Full Year) | | :--- | :--- | :--- | :--- | | **Total Income** | **203.27** | **230.12** | **176.59** | | **EBITDA** | **42.59** | **43.38** | **27.62** | | **EBITDA Margin** | **20.95%** | **18.85%** | **15.64%** | | **PAT** | **20.14** | **22.17** | **16.36** | **Key Financial Highlights:** * **Patient Volume:** Served **18.21 lakh patients** and conducted **53.98 lakh+ tests** in FY25. * **Margin Expansion:** Targeting consolidated **EBITDA margins of 30%-32% by FY27**. Pharmacy margins improved from **1.2% to 5.2%** in H1 FY26, with a **10% target**. * **Capital Allocation:** Deploying **₹100 Crore** for expansion, funded via a **₹104.13 Crore** preferential issue of warrants and IPO proceeds. * **Debt Management:** Successfully cleared significant term loans from **SBI** as of March 2025; Net worth exceeds **₹122.6 Cr** as of October 2025. --- ### **Risk Mitigation & Competitive Positioning** In a landscape of aggressive digital entrants and national chains, Chandan employs a **doctor-led marketing strategy** to protect margins and avoid the "cash-burn" associated with online-only models. * **B2C Loyalty:** The **Chandan Family Loyalty Card** has over **40 lakh cardholders**, adding **2 lakh new members per month**, ensuring a stable retail base (**58.78% of revenue**). * **Franchise Evolution:** Launching a franchise model as a fourth vertical only after establishing a low-cost operational base, aiming to offer better profitability than struggling competitors. * **Pricing Stability:** By focusing on B2B and institutional referrals, the company mitigates the pricing pressure caused by online aggregators. * **Future Roadmap:** Management intends to transition to a **Main Board IPO in FY27-28** as the company scales toward a **850-bed hospital capacity**.